The Memorial Sloan Kettering **Tow Center for Developmental Oncology** presents

2023 Robert Steel Symposium in **Developmental Oncology**

MAY 1-2, 2023 • NEW YORK, NY

Memorial Sloan Kettering Cancer Center

Overview

The **Robert Steel Symposium in Developmental Oncology** will bring together outstanding scientists from across the country to discuss the latest discoveries into the molecular mechanisms of cancers in children and young adults and the development of new approaches for their definitive therapy and control. This program will feature interactive discussions of fundamental and translational research to address unanswered questions in the field of developmental oncology.

There are **many unanswered questions that need to be addressed** for childhood and young adult cancers:

- What causes cancer in children and young adults without inheritance of cancer-predisposing mutations or exposure to environmental mutagens? How do predisposing alleles and exposures contribute to cancer development?
- What developmental processes are dysregulated to cause mutations and cell transformation in otherwise healthy tissues?
- How do mutations in developmental pathways involving transcription factors and epigenetic signaling cause cancer?
- How do we design effective therapeutics to block, activate, and modulate protein interactions that control transcription factors and other developmental regulators?
- How do we identify targets for immune therapy in developmental tumors that have relatively few mutations?

This two-day live, in-person Symposium will provide an **intimate and exciting setting to share new advances for these questions**. It will also allow an opportunity for established and young investigators to discuss new questions and interdisciplinary approaches of relevance to young-onset cancer biology.

Who Should Attend

The target audience for this Symposium includes scientists, physicians, APPs, nurses, and other healthcare providers interested in learning the latest advances in our understanding of the biology and therapy of childhood cancers.

Students and trainees are invited to attend this Symposium on a **complimentary basis**. Travel grants available upon request/approval.

Symposium Location

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY

While MSK requests that institutional guests are vaccinated against COVID-19, we are no longer requiring proof of vaccination. Additional details, including our current Health and Safety Protocols, can be accessed online:
mskcc.org/developmentaloncology

We invite attendees and faculty to a networking reception and dinner on Monday, May 1, Upstairs at The Kimberly.

Monday, May 1, 2023
6:00-9:00 PM

Upstairs at The Kimberly Hotel
145 East 50th Street
New York, NY
upstairsnyc.com

Upstairs at The Kimberly Hotel is a one-of-a-kind rooftop experience in the heart of New York City, focused on refined service in a relaxed luxurious setting. **RSVP to the reception is required during Symposium registration.**

#MSKDevOnc • #MSKkids
mskcc.org/developmentaloncology

Symposium Organizers

ALEX KENTSIS, MD, PHD
Associate Member
Molecular Pharmacology Program
Director, Tow Center for Developmental Oncology
Memorial Sloan Kettering Cancer Center

ANDREW KUNG, MD, PHD
Chair, Department of Pediatrics
Memorial Sloan Kettering Cancer Center

AGATA SMOGORZEWSKA, MD, PHD
Associate Professor
The Rockefeller University

The 2023 Robert Steel Symposium in Developmental Oncology is presented by the **Memorial Sloan Kettering (MSK) Tow Center for Developmental Oncology,** which unites scientists across MSK to develop fundamental insights into the molecular mechanisms of cancers in children and young adults, and to devise new approaches for definitive therapy and control.

For additional details, visit:
mskcc.org/research-programs/developmental-oncology

Schedule

Monday, May 1, 2023

7:45 AM	Registration and Breakfast
8:30 AM	**Introduction and Welcome** Alex Kentsis, MD, PhD
9:00 AM	**Genetic Predisposition to TP53-mutated Myeloid Malignancy** Akiko Shimamura, MD, PhD
9:35 AM	**Oncohistones: How to Promote Stalled Development and Neurodegeneration** Nada Jabado, MD, PhD

SESSION I

Tumor Lineage/Development

MODERATOR: Alex Kentsis, MD, PhD

10:10 AM	**Distinctive Embryonic Phylogenies and Driver Events of Infant Wilms Tumour** Henry Lee-Six, MB, PhD
10:25 AM	**The PIF1 Helicase Promotes Replication Through DNA Lesions in BRCA2-null Medulloblastoma** Danielle Keahi, BA
10:40 AM	**The Cbf-Glis Fusion Drives Mycn Expression to Promote Oncogenesis and Imparts Vulnerability to Brg1 Inhibitors in Pediatric Amkls.** Jay Sarthy, MD, PhD
10:55 AM	**Mesenchymal and Adrenergic Cell Lineage States in Neuroblastoma Possess Distinct Immunogenic Phenotypes** Satyaki Sengupta, MSc, PhD1
11:10 AM	**Defining Mechanisms of Somatic Evolution in Rhabdomyosarcoma (Rms) Relapse** Henry de Traux de Wardin, MD
11:25 AM	**Non-Invasive Diagnosis of Brainstem Gliomas in Pediatric, Adolescent, and Young Adult Patients through Cerebrospinal Fluid Cell-Free DNA Sequencing** Katherine Hill, BA
11:40 AM	Break
11:55 AM	**Structure and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Cancer** Cigall Kadoch, PhD
12:30 PM	**Specific Recurrent Secondary Mutations in Chromatin Regulatory Proteins and Other Transcription Factors May Serve to Enhance the Oncogenicity or Lethality of Canonical, Translocation-Generated, Chimeric Transcription Factors in Pediatric and Young Adult Sarcomas** Marc Ladanyi, MD
1:05 PM	Lunch Break

2:05 PM	**Targeted Inhibition of Epigenetic Modifiers in Leukemia** Jolanta Grembecka, PhD

SESSION II

Mechanisms of Resistance/New Targets

MODERATOR: Agata Smogorzewska, MD, PhD

2:40 PM	**Rewiring Cancer Drivers To Activate Apoptosis** Sai Gourisankar, BS
2:55 PM	**Amplicon Structure Creates Collateral Therapeutic Vulnerabilities in Neuroblastoma** Yi Bei, MSc
3:10 PM	**Fet Fusion Oncoproteins Create Functional Atm Defects in Ewing Sarcoma** Asmin Tulpule, MD, PhD
3:25 PM	**Phenotypic Screens Identify Genetic Regulators of Nanoparticle Delivery to Pediatric Tumors** Joelle Straehla, MD
3:40 PM	**Identifying Metabolic Vulnerabilities Of Pax3-Foxo1+ Rhabdomyosarcoma** Katrina Paras, BS
3:55 PM	**Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy** Yaniv Kazansky
4:10 PM	**Genomic and Functional Analysis to Elucidate Mechanisms of Osteosarcoma Metastasis and Therapy Resistance** Alejandro Sweet-Cordero, MD
4:45 PM	**Closing Remarks** Agata Smogorzewska, MD, PhD
5:00 PM	Adjourn

Networking Reception & Dinner

6:00 - 9:00 PM
Upstairs at The Kimberly
145 East 50th Street, New York, NY 10022

Join us for an opportunity to connect and interact with attendees and faculty at the Symposium Networking Reception and Dinner.
RSVP required during registration.

Tuesday, May 2, 2023

8:45 AM	Breakfast
9:35 AM	**Introduction and Welcome** Andrew Kung, MD, PhD
9:45 AM	**Transcriptional Dysregulations in AML - Insights from Meningioma-1** Kathrin Bernt, MD
10:20 AM	**Deciphering Genetic Predisposition to Childhood Leukemia** Vijay Sankaran, MD, PhD

SESSION III

Signaling/Transcriptional Regulation

MODERATOR: Andrew Kung, MD, PhD

10:55 AM	**RNA-Sequencing of Archived Tumors Reveals Dependencies and Drug Targets For Desmoplastic Small Round Cell Tumors** Madelyn Espinosa-Cotton, PhD
11:10 AM	Break
11:40 AM	**The Role of Immunosuppressive Tumor-Associated Macrophages in Mycn-Driven Neuroblastoma** Hiroyuki Yoda, PhD
11:55 AM	**Loss of Micrornas Cooperates with Tumor Suppressors to Initiate Myc-Dependent Metastatic Medulloblastoma** Sheila Alcantara Llaguno, MD, PhD
12:10 PM	**Reshaping the Dark Genome by Oncogenic Chimeric Transcription Factors** Olivier Delattre, MD, PhD
12:45 PM	**Closing Remarks** Alex Kentsis, MD, PhD
1:00 PM	Symposium Adjourn and Lunch

Symposium Faculty

SHEILA ALCANTARA, MD, PHD
Memorial Sloan Kettering Cancer Center

YI BEI, MSC
Charité – Universitätsmedizin Berlin

KATHRIN BERNT, MD
The Children's Hospital of Philadelphia

HENRY DE TRAUX, MD
Memorial Sloan Kettering Cancer Center

OLIVIER DELATTRE, MD, PHD
Institut Curie

MADELYN ESPINOSA COTTON, PHD
Memorial Sloan Kettering Cancer Center

SAI GOURISANKAR, BS
Stanford University

JOLANTA GREMBECKA, PHD
University of Michigan

KATHERINE HILL, BA
Memorial Sloan Kettering Cancer Center

NADA JABADO, MD, PHD
Montreal Children's Hospital
McGill University Health Center

CIGALL KADOCH, PHD
Dana-Farber Cancer Institute
Harvard Medical School

YANIV KAZANSKY
Memorial Sloan Kettering Cancer Center

DANI KEAHI, BA
The Rockefeller University

MARC LADANYI, MD
Memorial Sloan Kettering Cancer Center

HENRY LEE-SIX, MD, PHD
Wellcome Sanger Institute

KATRINA PARAS, BS
Memorial Sloan Kettering Cancer Center

VIJAY SANKARAN, MD, PHD
Dana-Farber Cancer Institute
Harvard Medical School

JAY SARTHY, MD, PHD
Seattle Children's Hospital

SATYAKI SENGUPTA, MSC, PHD
Dana-Farber Cancer Institute

AKIKO SHIMAMURA, MD, PHD
Dana-Farber Cancer Institute
Harvard Medical School

JOELLE STRAEHLA, MD
Dana-Farber Cancer Institute

ALEJANDRO SWEET-CORDERO, MD
University of California San Francisco

ASMIN TULPULE, MD, PHD
Memorial Sloan Kettering Cancer Center



HIROYUKI YODA, PHD
University of California San Francisco

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

At the conclusion of this Symposium, attendees will be able to:

- Explain biologic and developmental causes of childhood cancers.
- Review recently developed therapies for patients with childhood and young-onset cancers.
- Discuss new biologic questions in order to accelerate the development of definitive therapies for patients.

ACCREDITATION

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **10.00 *AMA PRA Category 1 Credits™***. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

> Detailed instructions on how to complete an evaluation and claim credit will be provided after the Symposium. Attendees must check-in at the start of the Symposium to receive access to the evaluation and CME certificate.

Memorial Sloan Kettering Cancer Center

ACCME ACCREDITED WITH COMMENDATION

REGISTER ONLINE:

mskcc.org/developmentaloncology

Registration Fees	
All Healthcare Providers	$25
Industry Professionals*	$45
Students and Trainees	Complimentary
MSK Employees	Complimentary

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

If you are a **student or trainee interested in attending this Symposium on a complimentary basis**, please email **devonc@mskcc.org** for a promotional code.

Students, residents, fellows, and postdocs **in need of financial support for travel and hotel**, please email **devonc@mskcc.org** with a request explaining your needs in 250 words or less.

Course registration includes continental breakfast, lunch, refreshment breaks, and an invitation to the networking reception on Monday evening. Please contact **cme@mskcc.org** at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

While MSK **requests that institutional guests are vaccinated against COVID-19**, we are no longer requiring proof of vaccination.

A registration discount is available for **MSK Alumni** and **MSK Cancer Alliance** to attend. If you are a member of one of these groups, contact **cme@mskcc.org** for details.

For additional details, including the cancellation policy, visit: **mskcc.org/developmentaloncology**

The **Tow Foundation** has been a leading benefactor of Memorial Sloan Kettering since 1976, supporting areas including cell therapies, inflammation and cancer, radiotheranostics, skin cancer research, and, especially, pediatric cancer research. The Foundation's visionary and generous 2018 commitment established the **Tow Center for Developmental Oncology**, which seeks to unite scientists across MSK to develop fundamental insights into the molecular mechanisms of cancers in children and young adults and to devise new approaches for definitive therapy and control.

The **Robert Steel Foundation for Pediatric Cancer Research** was established to honor the memory of Robert Steel, who died in 1984 at the age of eighteen after a heroic two-year struggle against rhabdomyosarcoma. Throughout the years, the Foundation supported MSK programs and initiatives devoted to speeding progress against childhood cancers, and its farsighted generosity has made **The Robert Steel Symposium in Developmental Oncology** possible. By bringing together leading scientists to address the latest challenges and opportunities in pediatric cancer research and treatment, **The Robert Steel Symposium in Developmental Oncology** continues to advance the vital work launched by the **Robert Steel Foundation for Pediatric Cancer Research** more than three decades ago.

Memorial Sloan Kettering
Cancer Center

mskcc.org/developmentaloncology